Sunmax Biotechnology Co., Ltd. Stock

Equities

4728

TW0004728001

Biotechnology & Medical Research

End-of-day quote Taipei Exchange 06:00:00 2024-04-22 pm EDT 5-day change 1st Jan Change
222.5 TWD +0.23% Intraday chart for Sunmax Biotechnology Co., Ltd. -1.77% +9.07%
Sales 2022 1.4B 43.06M Sales 2023 1.69B 51.95M Capitalization 11.11B 342M
Net income 2022 534M 16.43M Net income 2023 626M 19.26M EV / Sales 2022 4.75 x
Net cash position 2022 754M 23.18M Net cash position 2023 793M 24.38M EV / Sales 2023 6.11 x
P/E ratio 2022
13.9 x
P/E ratio 2023
17.8 x
Employees -
Yield 2022
6.99%
Yield 2023
-
Free-Float 53.12%
More Fundamentals * Assessed data
Dynamic Chart
Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Sunmax Biotechnology Co., Ltd.(TPEX:4728) added to S&P Global BMI Index CI
Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter and Half Year Ended June 30, 2021 CI
Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
More news
1 day+0.23%
1 week-1.77%
Current month-3.68%
1 month+5.45%
3 months+10.70%
6 months+17.41%
Current year+9.07%
More quotes
1 week
217.00
Extreme 217
230.00
1 month
211.00
Extreme 211
245.00
Current year
191.50
Extreme 191.5
252.00
1 year
175.00
Extreme 175
300.00
3 years
64.60
Extreme 64.6
300.00
5 years
51.00
Extreme 51
300.00
10 years
21.25
Extreme 21.25
300.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 14-05-13
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - 02-09-10
Members of the board TitleAgeSince
Chairman - -
Director/Board Member - 06-03-28
Chief Executive Officer - 14-05-13
More insiders
Date Price Change Volume
24-04-23 222.5 +0.23% 16,756
24-04-22 222 0.00% 28,244
24-04-19 222 -2.63% 84,943
24-04-18 228 +0.88% 35,248
24-04-17 226 -0.22% 38,955

End-of-day quote Taipei Exchange, April 22, 2024

More quotes
SunMax Biotechnology Co., Ltd. is a Taiwan-based company principally engaged in research, development, production and distribution of collagen implants and related products. The Company's major products include collagen, collagen implants, microfiber collagen hemostat, collagen absorbable hemostat pads, healthcare products, as well as medical collagen application equipment. Its products are applied in medical and beauty care industrials. The Company distributes its products principally in Taiwan, Mainland China and other regions.
More about the company